Citation map · Study

SZodixStudyAcademic Library

Shelves Open access

Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated

Sustainability and affordability of cancer drugs: a novel pricing model

5 references·6 citing·33 second hop

FromToDepth

this work references cited by second hop

References

2016Innovation in the pharmaceutical industry: New estimates of R&D costs3,621 cited
2013Economic burden of cancer across the European Union: a population-based cost analysis1,009 cited
2014Thresholds for the cost–effectiveness of interventions: alternative approaches851 cited
2017Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13600 cited
2017Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval503 cited

Cited by

2021Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications75 cited
2020What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings73 cited
2020Unequal Access to Newly Registered Cancer Drugs Leads to Potential Loss of Life-Years in Europe72 cited
2020Integrative Review of Managed Entry Agreements: Chances and Limitations56 cited
2021Evidence-based public policy making for medicines across countries: findings and implications for the future55 cited
2020Cost-effectiveness of adding atezolizumab to first-line chemotherapy in patients with advanced triple-negative breast cancer52 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work